Breakthrough trial aims to slash death rates in vulnerable HIV/TB patients
NCT ID NCT04738812
Summary
This large Phase 3 trial tested whether a stronger, intensified tuberculosis (TB) treatment regimen could save more lives than standard TB treatment in HIV patients hospitalized with TB and severely weakened immune systems (CD4 ≤ 100 cells/μL). It enrolled 1,330 adults and adolescents across six countries in Africa and Asia. The study compared the intensified regimen—which included higher doses of key TB drugs plus steroids and a deworming medicine—against the standard World Health Organization treatment over 48 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ignace Deen Hospital
Conakry, Guinea
-
Jamot Hospital
Yaoundé, Cameroon
-
MACHAVA Hospital
Maputo, Mozambique
-
Mbarara Regional Referral hospital
Mbarara, Uganda
-
National Center for HIV/AIDS, Dermatology and STD (NCHADS)
Phnom Penh, Cambodia
-
University Teaching Hospital
Lusaka, Zambia
Conditions
Explore the condition pages connected to this study.